News & Updates

A blood test for identifying Alzheimer’s disease (AD) among individuals with cognitive symptoms appears to be highly accurate, outperforming traditional methods used in the primary and secondary care settings, according to a study.

Pathological response rates are high for neoadjuvant dabrafenib plus trametinib among patients with stage III melanoma, but recurrence-free survival (RFS) rates are low, reports a study.

First-line treatment with nivolumab (NIVO) in combination with ipilimumab (IPI) results in better health-related quality of life (HRQOL) and fewer symptoms, when compared with chemotherapy, in patients with centrally confirmed microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), as shown in the CheckMate 8HW study presented at ESMO GI 2024.

Combination therapy with sodium-glucose transporter inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1ra) prevents heart failure and improves long-term survival in a real-world population as compared with SGLT2i or GLP1ra monotherapy, according to a study.

In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.